# Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease

> **NCT05453539** · PHASE1 · TERMINATED · sponsor: **Alzeca Biosciences, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** DSPE-DOTA-Gd Liposomal Injection

## Key facts

- **NCT ID:** NCT05453539
- **Lead sponsor:** Alzeca Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-09
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453539, "Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05453539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*